We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · July 04, 2021

Gene Expression Signature Correlates With Outcomes in mRCC Patients Treated With Everolimus ± a Vascular Disrupting Agent

Molecular Cancer Therapeutics


Additional Info

Molecular Cancer Therapeutics
Gene Expression Signature Correlates With Outcomes in Metastatic Renal Cell Carcinoma Patients Treated With Everolimus Alone or With a Vascular Disrupting Agent
Mol Cancer Ther 2021 Jun 09;[EPub Ahead of Print], ES Yang, AH Nassar, E Adib, OA Jegede, S Abou Alaiwi, DL Della Manna, DA Braun, M Zarei, H Du, SK Pal, G Naik, GP Sonpavde

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading